Clinical trials: Persistent
Atrial Fibrillation
HeartLight X3 Endoscopic Ablation System With Excalibur Balloon for Treatment of Symptomatic Persistent AF
The objective of the study is to demonstrate the improved ablation and procedure times of the HeartLight X3 compared to the original HeartLight catheter in the treatment of persistent atrial fibrillation.
- Trial name
- NCT03988244
- Testing
- HeartLight X3
- Where
- Czechia
- Volunteers
- 11 people
- Sponsor
- CardioFocus
Atrial Fibrillation, Paroxysmal Atrial Fibrillation
Feasibility Study on the FARAVIEW Technology
The purpose of this study is to gather data regarding the utilization of the FARAVIEW™ feature of the RHYTHMIA HDx Mapping System when used in conjunction with the FARAWAVE NAV Pulsed Field Ablation catheter in subjects…
- Conditions
- Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Trial name
- NAVIGATE PF (NCT06175234)
- Testing
- Ablation Treatment
- Where
- 3 sites in Czechia, Ireland and 1 more
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
The study is designed to be a randomized, open, multi-center, phase IIa/IIb seamless adaptive trial. Phase IIa: The study consists of a screening period, a core treatment period, an open label extension period, and a safety…
- Trial name
- NCT05232149
- Testing
- Orelabrutinib( lower dose), Orelabrutinib( higher dose)
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Asthma
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
- Trial name
- STAR (NCT00445107)
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 198 people
- Sponsor
- Organon and Co
Asthma
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of…
- Trial name
- NCT01147744
- Testing
- Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg
- Where
- 84 sites in United States, Bulgaria and 4 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Asthma, COPD
A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)
This study will compare the patient handling of Flutiform® pMDI (pressurised metered dose inhaler) and a breath activated device (BAI).
- Trial name
- NCT01739387
- Testing
- Flutiform® pMDI and Breath Actuated Inhaler (BAI)
- Where
- 2 sites in United Kingdom
- Volunteers
- 332 people
- Sponsor
- Mundipharma Research Limited
Asthma
Efficacy of QAX576 in Asthma
The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
- Trial name
- NCT01130064
- Testing
- QAX576
- Where
- 52 sites in United States, Argentina and 5 more
- Volunteers
- 259 people
- Sponsor
- Novartis Pharmaceuticals
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Persistent Atrial Fibrillation
Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats
The purpose of this study is to demonstrate that the Estech COBRA Surgical System is an effective treatment for patients with irregular heart beats who are undergoing heart surgery.
- Trial name
- NCT01683045
- Testing
- The Estech COBRA® Surgical System
- Where
- 13 sites in United States
- Volunteers
- 6 people
- Sponsor
- Endoscopic Technologies, Inc
Asthma
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler…
- Trial name
- NCT02040766
- Testing
- Beclomethasone dipropionate BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI
- Where
- 102 sites in United States, Croatia and 3 more
- Volunteers
- 628 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
This study is researching an experimental drug called ALN-CFB. The study is focused on people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are currently taking a complement component C5 inhibitor ("C5-inhibitor") and…
- Trial name
- NCT07187401
- Testing
- ALN-CFB
- Where
- 8 sites in Canada, South Korea and 1 more
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Lung Disease
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
The purpose of this research study is to evaluate the effect of AZD3199 on the electrical activity of the heart. The effect of AZD3199 will be compared to a licensed antibiotic (moxifloxacin).
- Trial name
- NCT01222442
- Testing
- AZD3199, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Persistent Atrial Fibrillation
Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
The study is a prospective, multicenter, randomized study to assess the safety and effectiveness of FIRM procedures followed by conventional ablation including PVI versus a standard PVI procedure for the treatment of persistent…
- Trial name
- REAFFIRM (NCT02274857)
- Testing
- Standard PVI Ablation, FIRM-Guided Procedure and PVI
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 350 people
- Sponsor
- Abbott Medical Devices
Asthma, Bronchial, Bronchial Asthma
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
- Trial name
- NCT00189722
- Testing
- Tacrolimus
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 160 people
- Sponsor
- Astellas Pharma Inc
Atrial Fibrillation
Persistent AF Catheter Ablation: Re-PVI Vs. Re-PVI + Continuous Complex Activity Mapping and Ablation - AF-CAM
Major objective is to compare the efficacy of adding additional ablation step (targeting areas of complex, continuous electrical activity in LA) beyond Re-PVI during catheter ablation of Atrial Fibrillation (AF) in patients…
- Trial name
- AF-CAM (NCT05496088)
- Testing
- Re-PVI only, Re-PVI + substrate ablation
- Where
- 3 sites in Germany
- Volunteers
- 56 people
- Sponsor
- Asklepios proresearch
Heart Failure, Volume Overload
Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0
This study is a multi-center, prospective, randomized (2:1), open-label study to evaluate the safety and efficacy of DSR therapy using the Infusate 2.0 peritoneal solution (composed of 30% icodextrin and 10% dextrose) in diuretic…
- Trial name
- MOJAVE (NCT05965934)
- Testing
- Direct Sodium Removal Infusate 2.0
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sequana Medical N.V.
Sunscreening Agents
18750-Sun Protection Factor Assay
To evaluate the Sun Protection Factor (SPF) efficacy on human skin.
- Trial name
- SPF Assay (NCT02741466)
- Testing
- Coppertone (BAY987517)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bayer
Asthma
SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is…
- Trial name
- NCT00455923
- Testing
- Seretide, Flixotide
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Bioequivalence
A Study Comparing Oxymetazoline 1% Cream to RHOFADE
randomized, double-blind, placebo controlled
- Trial name
- NCT05148689
- Testing
- Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.